A class action lawsuit has been filed against Replimune Group, Inc. alleging the company failed to disclose critical issues related to its FDA Biologics License Application (BLA). The lawsuit claims Replimune did not address FDA concerns about study design and submitted incomplete data from a small patient group, likely leading to FDA rejection of the BLA. Investors argue that the company's positive statements about its business and prospects were misleading. The case is pending in the U.S. District Court for the District of Massachusetts, with a lead plaintiff motion deadline on October 5, 2026.
XTEND AI Robotics began trading on the NYSE on September 4 after merging with JFB Construction Holdings, marking a new chapter as a public company. Stoke Space is advancing its Nova Pathfinder and Nova Block 2 launch vehicles, aiming for a 2027 orbit...
Michael Saylor's Strategy did not buy or sell any Bitcoin from Aug. 31 to Sept. 7 but repurchased $176.3 million in preferred stock and doubled its buyback program to $2 billion. Meanwhile, Strive bought 1,375 BTC for about $109 million, increasing i...
Global Net Lease (GNL) has seen its dividend coverage decline following several dividend cuts in 2023, despite offering an attractive 8.33% dividend yield. The company maintains an investment-grade BBB- credit rating and has engaged in stock buybacks...
CoreWeave has shifted its business model to focus on long-term, take-or-pay contracts backed by a $129 billion contracted order book, providing high revenue visibility and durability. Currently, only 36% of its contracted GPU capacity is active, indi...
Uber's profits doubled and free cash flow surpassed $10 billion, yet its stock price remains flat and down over the past year. The market appears to be pricing in risks from autonomous vehicle rivals like Waymo, which could disrupt Uber's dominance i...
